Optellum Announces Agreement with Bristol Myers Squibb to Leverage AI to Boost Early Lung Cancer Diagnosis

Rapidly growing lung health company aims to redefine early diagnosis and precision lung cancer care using multi-modal artificial intelligence (AI).

OXFORD, United Kingdom and HOUSTON, April 15, 2025 /PRNewswire/ -- Optellum, a global leader in AI-driven clinical decision support for early lung cancer diagnosis, has entered an agreement with Bristol Myers Squibb (NYSE: BMY), to leverage AI in early diagnosis and precision lung cancer care. Under the agreement, Optellum will apply its AI-powered imaging & clinical decision support platform to evaluate the real-world impact on patient outcomes.

Read more at prnewswire.com